Article
Modulation of macrophage polarization with acute administration of Vericiguat after myocardial infarction.
American journal of physiology. Heart and circulatory physiology - 1 Mar 2026
Dempster Thomas, Corker Alexa, Vu Kim, Troncoso Miguel, Bradley Norma, Hazzard Amber, Milligan Kailee, Macaulay Bryce, Dasgupta Shaoni, Li Mei, DeLeon-Pennell Kristine Y
Abstract excerpt
Vericiguat (Merck, marketed as Verquvo) is a soluble guanylate cyclase stimulator that is Food and Drug Administration-approved for use in heart failure patients with reduced or mildly reduced ejection fraction (HFrEF and HFmrEF) to decrease heart failure hospitalization and cardiovascular mortality. We hypothesized that earlier administration of vericiguat post-myocardial infarction (MI) would reduce the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
